Drugs / CAR-GPC3 T Cells
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03884751 | Aug 2019 → May 2021 | hepatocellular carcinoma | CARsgen Therapeutics Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03980288 | Jul 2019 → Dec 2020 | hepatocellular carcinoma | Zhejiang University | Completed | No outcome recorded |
| Phase 1 | NCT02876978 | Mar 2016 → Oct 2017 | squamous cell lung carcinoma | CARsgen Therapeutics Co., Ltd. | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05926726 | Jan 2023 → Dec 2025 overdue | hepatocellular carcinoma | RenJi Hospital | Recruiting | No outcome recorded |
| — | NCT03146234 | Mar 2017 → Oct 2018 | hepatocellular carcinoma | RenJi Hospital | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2024-03-12 | SOTIO a.s. | Results SOTIO Presents New Preclinical Data on Enhanced CAR T-Cell Therapies at AACR Annual Meeting sotio.com ↗
Compared to unmodified CAR T cells and CAR T cells enhanced with GOT2 solely, CAR T cells enhanced with GOT2 and TIGAR showed better tumor infiltration, lower levels of exhaustion, and superior anti-tumor activity in a mouse model of solid tumors. |
| 2022-11-10 | SOTIO a.s. | Results SOTIO Presents Preclinical Data from BOXR CAR-T Program and Trial Design of Phase 2 AURELIO-04 Study at SITC Annual Meeting sotio.com ↗
Findings on the mechanism of action from the BOXR CAR-T platform indicate improved metabolic function and preservation of early memory subsets of T cells. |
| 2022-08-18 | CARsgen Therapeutics Co., Ltd. | Results Case Report of Long Term Complete Response in Hepatocellular Carcinoma to CARsgen's GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology carsgen.com ↗
This patient obtained partial responses (PR) from the 3rd month and achieved CR in the 12th month after the first cycle of CT011 infusion. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-03-12 | SOTIO a.s. | SOTIO Presents New Preclinical Data on Enhanced CAR T-Cell Therapies at AACR Annual Meeting sotio.com ↗ |
| 2022-11-10 | SOTIO a.s. | SOTIO Presents Preclinical Data from BOXR CAR-T Program and Trial Design of Phase 2 AURELIO-04 Study at SITC Annual Meeting sotio.com ↗ |
| 2022-08-18 | CARsgen Therapeutics Co., Ltd. | Case Report of Long Term Complete Response in Hepatocellular Carcinoma to CARsgen's GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology carsgen.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-GPC3 T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02876978 ↗ |
| Modality | Cell therapy | “lentivirus-transduced CAR-GPC3 T cells” NCT02876978 ↗ |
| Route | Intravenous | “Intravenous infusion of CAR-GPC3 T cells” NCT02876978 ↗ |
| Target | GPC3 | “CAR-GPC3 T cells targeting GPC3” NCT02876978 ↗ |